+

WO1998049307A1 - Recepteurs de mammiferes analogues de la cytokine - Google Patents

Recepteurs de mammiferes analogues de la cytokine Download PDF

Info

Publication number
WO1998049307A1
WO1998049307A1 PCT/US1998/008865 US9808865W WO9849307A1 WO 1998049307 A1 WO1998049307 A1 WO 1998049307A1 US 9808865 W US9808865 W US 9808865W WO 9849307 A1 WO9849307 A1 WO 9849307A1
Authority
WO
WIPO (PCT)
Prior art keywords
leu
gly
ser
pro
arg
Prior art date
Application number
PCT/US1998/008865
Other languages
English (en)
Inventor
Si Lok
Scott R. Presnell
Anna C. Jelmberg
Teresa Gilbert
Theodore E. Whitmore
Donald C. Foster
Robyn L. Adams
Joyce M. Lehner
Original Assignee
Zymogenetics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics, Inc. filed Critical Zymogenetics, Inc.
Priority to AU72760/98A priority Critical patent/AU7276098A/en
Publication of WO1998049307A1 publication Critical patent/WO1998049307A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons

Definitions

  • hormones and polypeptide growth factors are controlled by hormones and polypeptide growth factors. These diffusable molecules allow cells to communicate with each other and act in concert to form cells and organs, and to repair and regenerate damaged tissue.
  • hormones and growth factors include the steroid hormones (e.g. estrogen, testosterone) , parathyroid hormone, follicle stimulating hormone, the interleukins, platelet derived growth factor (PDGF) , epidermal growth factor (EGF) , granulocyte-macrophage colony stimulating factor (GM-CSF) , erythropoietin (EPO) and calcitonin.
  • Receptors may be integral membrane proteins that are linked to signaling pathways within the cell, such as second messenger systems.
  • Other classes of receptors are soluble molecules, such as the transcription factors.
  • cytokines molecules that promote the proliferation and/or differentiation of cells.
  • cytokines include erythropoietin (EPO) , which stimulates the development of red blood cells; thrombopoietin (TPO) , which stimulates development of cells of the megakaryocyte lineage; and granulocyte-colony stimulating factor (G-CSF) , which stimulates development of neutrophils.
  • EPO erythropoietin
  • TPO thrombopoietin
  • G-CSF granulocyte-colony stimulating factor
  • the present invention addresses this need by providing a novel mammalian cytokine-like receptor called mammalian Zcytor ⁇ , and related compositions and methods.
  • the present invention provides an isolated human polynucleotide encoding a ligand-binding human receptor polypeptide.
  • the polypeptide comprises a sequence of amino acids containing (a) the amino acid residues of SEQ ID NO: 17, residues 35 to 422 of SEQ ID NO:2; (b) allelic variants of (a); and (c) sequences that are at least 90%, 95% or 99% identical to (a) or (b) .
  • the polypeptide is comprised of amino acid residues 30 to and including amino acid residue 422 of SEQ ID NO : 2.
  • the present invention also provides for a polynucleotide encoding another allelic variant of SEQ ID NO: 2 which is a human polypeptide receptor and is defined by SEQ ID NO: 4 in particular the polypeptide comprised of a sequence of amino acids containing (a) the amino acid residues of SEQ ID NO: 18, residues 34 to 425 of SEQ ID NO: 4; (b) allelic variants of (a); and (c) sequences that are at least 90%, 95% or 99% identical to (a) or (b) .
  • the polypeptide is comprised of amino acid residues 29 to and including amino acid residue 425 of SEQ ID NO : 4.
  • polynucleotides of the present invention encode the amino acid sequence of SEQ ID NO: 21 which is a soluble receptor of SEQ ID NO: 17 that does not contain a C-terminus phosphatidylinositol signal sequence;
  • the amino acid sequence of SEQ ID NO: 20 is a Zcytor5 polypeptide of SEQ ID NO : 2 having an alternative N-terminus cleavage site;
  • SEQ ID NO: 22 which has an alternative N-terminus cleavage site of the Zcytor5 polypeptide of SEQ ID NO : 4 ;
  • SEQ ID NO: 23 which is an amino acid of SEQ ID NO: 18 that does not contain a C-terminus phosphatidylinositol signal sequence and the amino acid sequences defined by SEQ ID NOs: 24-31 which are variants of the Zcytor5 polypeptide of SEQ ID NO:4.
  • Another embodiment of the present invention is a polynucleotide which encodes rat Zcytor5.
  • a polynucleotide which encodes a rat polypeptide containing (a) the amino acid sequence of SEQ ID NO: 19 residues 41 to 425 of SEQ ID NO: 6; (b) allelic variants of (a) ; and (c) sequences that are at least 90%, 95% or 99% identical to (a) or (b) .
  • an expression vector comprising (a) a transcription promoter; (b) a DNA segment encoding a secretory peptide and a ligand-binding Zcyotor5 receptor polypeptide, containing an amino acid sequence as described above .
  • a cultured eukaryotic cell into which has been introduced an expression vector as disclosed above, wherein said cell expresses a mammalian Zcytor5 receptor polypeptide encoded by the DNA segment .
  • polypeptide comprises a sequence of amino acids containing (a) the amino acid sequence of SEQ ID NO: 17, residues 35 to 422 of SEQ ID NO: 2; (b) allelic variants of (a) ; and (c) sequences that are at least 90%, 95% or 99% identical to (a) or (b) .
  • the polypeptide is comprised of amino acid residues 30 to and including amino acid residue 422 of SEQ ID NO : 2.
  • the present invention also provides for another allelic variant of SEQ ID NO: 2 which is a human polypeptide receptor and is defined by SEQ ID NO: 4 in particular the polypeptide is comprised of a sequence of amino acids containing (a) the amino acid sequence of SEQ ID NO: 18, residues 34 to 425 of SEQ ID NO : 4 ; (b) allelic variants of (a) ; and (c) sequences that are at least 90%, 95% or 99% identical to (a) or (b) .
  • the polypeptide is comprised of residues 29 to 425 of SEQ ID NO: 4.
  • Another embodiment of the present invention is a rat Zcytor5 polypeptide containing (a) the amino acid sequence of SEQ ID NO: 19, residues 41 to 425 of SEQ ID NO:6; (b) allelic variants of (a); and (c) sequences that are at least 80% identical to (a) or (b) .
  • a chimeric polypeptide consisting essentially of a first portion and a second portion joined by a peptide bond.
  • the first portion of the chimeric polypeptide consists essentially of a Zcytor5 receptor polypeptide as described above.
  • the invention also provides expression vectors encoding the chimeric polypeptides and host cells transfected to produce the chimeric polypeptides.
  • the invention also provides a method for detecting a ligand within a test sample, comprising contacting a test sample with a Zcytor5 polypeptide as disclosed above, and detecting binding of the polypeptide to ligand in the sample.
  • the polypeptide can be membrane bound within a cultured cell, wherein the detecting step comprises measuring a biological response in the cultured cell.
  • the polypeptide is immobilized on a solid support.
  • An additional embodiment of the present invention relates to a peptide or polypeptide which has the amino acid sequence of an epitope-bearing portion of a Zcytor5 polypeptide having an amino acid sequence described above.
  • Peptides or polypeptides having the amino acid sequence of an epitope-bearing portion of a Zcytor5 polypeptide of the present invention include portions of such polypeptides with at least nine, preferably at least 15 and more preferably at least 30 to 50 amino acids, although epitope-bearing polypeptides of any length up to and including the entire amino acid sequence of a polypeptide of the present invention described above are also included in the present invention. Examples of said polypeptides are defined by the amino acid sequences of SEQ ID NOs: 32-37.
  • affinity tag is used herein to denote a polypeptide segment that can be attached to a second polypeptide to provide for purification or detection of the second polypeptide or provide sites for attachment of the second polypeptide to a substrate.
  • Affinity tags include a poly-histidine tract, protein A [Nilsson et al , EMBO J. 1:1075 (1985); Nilsson et al . ,
  • allelic variant denotes any of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation arises naturally through mutation, and may result in phenotypic polymorphism within populations. Gene mutations can be silent (no change in the encoded polypeptide) or may encode polypeptides having altered amino acid sequence.
  • allelic variant is also used herein to denote a protein encoded by an allelic variant of a gene.
  • allelic variant is used herein to denote any of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation arises naturally through mutation, and may result in phenotypic polymorphism within populations. Gene mutations can be silent (no change in the encoded polypeptide) or may encode polypeptides having altered amino acid sequence.
  • allelic variant is also used herein to denote a protein encoded by an allelic variant of a gene .
  • amino-terminal and “carboxyl- terminal” are used herein to denote positions within polypeptides. Where the context allows, these terms are used with reference to a particular sequence or portion of a polypeptide to denote proximity or relative position. For example, a certain sequence positioned carboxyl- terminal to a reference sequence within a polypeptide is located proximal to the carboxyl terminus of the reference sequence, but is not necessarily at the carboxyl terminus of the complete polypeptide.
  • complement/anti-complement pair denotes non-identical moieties that form a non-covalently associated, stable pair under appropriate conditions.
  • biotin and avidin are prototypical members of a complement/anti-complement pair.
  • Other exemplary complement/anti-complement pairs include receptor/ligand pairs, antibody/antigen (or hapten or epitope) pairs, sense/antisense polynucleotide pairs, and the like.
  • the complement/anti-complement pair preferably has a binding affinity of ⁇ 10 9 M -1 .
  • polynucleotide molecule is a polynucleotide molecule having a complementary base sequence and reverse orientation as compared to a reference sequence.
  • sequence 5 ' ATGCACGGG 3 ' is complementary to 5 ⁇ CCCGTGCAT 3 ' .
  • contig denotes a polynucleotide that has a contiguous stretch of identical or complementary sequence to another polynucleotide. Contiguous sequences are said to "overlap" a given stretch of polynucleotide sequence either in their entirety or alone a partial stretch of the polynucleotide. For example, representative contigs to the polynucleotide sequence 5'- ATGGCTTAGCTT-3 'are 5 ' -TAGCTTgagtct-3 ' and 3 ' -gtcgacTACCGA- 5' .
  • degenerate nucleotide sequence denotes a sequence of nucleotides that includes one or more degenerate codons (as compared to a reference polynucleotide molecule that encodes a polypeptide) .
  • Degenerate codons contain different triplets of nucleotides, but encode the same amino acid residue (i.e., GAU and GAC triplets each encode Asp) .
  • expression vector is used to denote a DNA molecule, linear or circular, that comprises a segment encoding a polypeptide of interest operably linked to additional segments that provide for its transcription.
  • additional segments include promoter and terminator sequences, and may also include one or more origins of replication, one or more selectable markers, an enhancer, a polyadenylation signal, etc.
  • Expression vectors are generally derived from plasmid or viral DNA, or may contain elements of both.
  • isolated when applied to a polynucleotide, denotes that the polynucleotide has been removed from its natural genetic milieu and is thus free of other extraneous or unwanted coding sequences, and is in a form suitable for use within genetically engineered protein production systems.
  • isolated molecules are those that are separated from their natural environment and include cDNA and genomic clones.
  • Isolated DNA molecules of the present invention are free of other genes with which they are ordinarily associated, but may include naturally occurring 5 ' and 3 ' untranslated regions such as promoters and terminators. The identification of associated regions will be evident to one of ordinary skill in the art, for example, Dynan and Tijan, Nature 316 : 114 - 18 (1985) .
  • an "isolated" polypeptide or protein is a polypeptide or protein that is found in a condition other than its native environment, such as apart from blood and animal tissue.
  • the isolated polypeptide is substantially free of other polypeptides, particularly other polypeptides of animal origin. It is preferred to provide the polypeptides in a highly purified form, i.e. greater than 95% pure, more preferably greater than 99% pure.
  • the term “isolated” does not exclude the presence of the same polypeptide in alternative physical forms, such as dimers or alternatively glycosylated or derivatized forms.
  • “Operably linked”, when referring to DNA segments, indicates that the segments are arranged so that they function in concert for their intended purposes, e.g. transcription initiates in the promoter and proceeds through the coding segment to the terminator.
  • ortholog denotes a polypeptide or protein obtained from one species that has homology to an analogous polypeptide or protein from a different species.
  • polypeptide or protein obtained from a given species that has homology to a distinct polypeptide or protein from that same species.
  • polynucleotide is a single- or double- stranded polymer of deoxyribonucleotide or ribonucleotide bases read from the 5' to the 3' end.
  • Polynucleotides include RNA and DNA, and may be isolated from natural sources, synthesized in vi tro, or prepared from a combination of natural and synthetic molecules.
  • polypeptide is a polymer of amino acid residues joined by peptide bonds, whether produced naturally or synthetically. Polypeptides of less than about 10 amino acid residues are commonly referred to as “peptides” .
  • promoter is used herein for its art- recognized meaning to denote a portion of a gene containing DNA sequences that provide for the binding of RNA polymerase and initiation of transcription. Promoter sequences are commonly, but not always, found in the 5' non-coding regions of genes.
  • a “protein” is a macromolecule comprising one or more polypeptide chains.
  • a protein may also comprise non- peptidic components, such as carbohydrate groups. Carbohydrates and other non-peptidic substituents may be added to a protein by the cell in which the protein is produced, and will vary with the type of cell. Proteins are defined herein in terms of their amino acid backbone structures; substituents such as carbohydrate groups are generally not specified, but may be present nonetheless.
  • the term "receptor” denotes a cell-associated protein that binds to a bioactive molecule (i.e., a ligand) and mediates the effect of the ligand on the cell.
  • Membrane-bound receptors are characterized by a multi- domain structure comprising an extracellular ligand- binding domain and an intracellular effector domain that is typically involved in signal transduction. Binding of ligand to receptor results in a conformational change in the receptor that causes an interaction between the effector domain and other molecule (s) in the cell. This interaction in turn leads to an alteration in the metabolism of the cell. Metabolic events that are linked to receptor-ligand interactions include gene transcription, phosphorylation, dephosphorylation, increases in cyclic AMP production, mobilization of cellular calcium, mobilization of membrane lipids, cell adhesion, hydrolysis of inositol lipids and hydrolysis of phospholipids .
  • receptors can be membrane bound, cytosolic or nuclear; monomeric (e.g., thyroid stimulating hormone receptor, beta-adrenergic receptor) or multimeric (e.g., PDGF receptor, growth hormone receptor, IL-3 receptor, GM-CSF receptor, G-CSF receptor, erythropoietin receptor and IL-6 receptor) .
  • monomeric e.g., thyroid stimulating hormone receptor, beta-adrenergic receptor
  • multimeric e.g., PDGF receptor, growth hormone receptor, IL-3 receptor, GM-CSF receptor, G-CSF receptor, erythropoietin receptor and IL-6 receptor
  • secretory signal sequence denotes a DNA sequence that encodes a polypeptide (a "secretory peptide") that, as a component of a larger polypeptide, directs the larger polypeptide through a secretory pathway of a cell in which it is synthesized.
  • the larger polypeptide is commonly cleaved to remove the secretory peptide during transit through the secretory pathway.
  • splice variant is used herein to denote alternative forms of RNA transcribed from a gene.
  • Splice variation arises naturally through use of alternative splicing sites within a transcribed RNA molecule, or less commonly between separately transcribed RNA molecules, and may result in several mRNAs transcribed from the same gene.
  • Splice variants may encode polypeptides having altered amino acid sequence.
  • the term splice variant is also used herein to denote a protein encoded by a splice variant of an mRNA transcribed from a gene .
  • a "soluble receptor” is a receptor polypeptide that is not bound to a cell membrane. Soluble receptors are most commonly ligand-binding receptor polypeptides that lack transmembrane and cytoplasmic domains. Soluble receptors can comprise additional amino acid residues, such as affinity tags that provide for purification of the polypeptide or provide sites for attachment of the polypeptide to a substrate, or immunoglobulin constant region sequences. Many cell-surface receptors have naturally occurring, soluble counterparts that are produced by proteolysis or translated from alternatively spliced mRNAs. Receptor polypeptides are said to be substantially free of transmembrane and intracellular polypeptide segments when they lack sufficient portions of these segments to provide membrane anchoring or signal transduction, respectively.
  • the present invention is based in part upon the discovery of a novel DNA sequence that encodes a protein having the structure of a cytokine receptor, including the conserved WSXWS motif. Analysis of the tissue distribution of the mRNA corresponding to this novel DNA showed that expression was present in highest amounts in placenta, thyroid, heart and skeletal muscle with lower levels in prostate and trachea. Cytokine receptors subunits are characterized by a multi-domain structure comprising a ligand-binding domain and an effector domain that is typically involved in signal transduction.
  • Multimeric cytokine receptors include homodimers (e.g., PDGF receptor ⁇ and ⁇ isoforms, erythropoietin receptor, MPL [thrombopoietin receptor] , and G-CSF receptor) , heterodimers whose subunits each have ligand-binding and effector domains (e.g., PDGF receptor ⁇ isoform), and multimers having component subunits with disparate functions (e.g., IL-2,
  • IL-3, IL-4, IL-5, IL-6, IL-7, and GM-CSF receptors Some receptor subunits are common to a plurality of receptors.
  • the AIC2B subunit which cannot bind ligand on its own but includes an intracellular signal transduction domain, is a component of IL-3 and GM-CSF receptors .
  • Many cytokine receptors can be placed into one of four related families on the basis of their structures and functions. Hematopoietic receptors, for example, are characterized by the presence of a domain containing conserved cysteine residues and the WSXWS motif.
  • Additional domains including protein kinase domains; fibronectin type III domains; and immunoglobulin domains, which are characterized by disulfide-bonded loops, are present in certain hematopoietic receptors. Cytokine receptor structure has been reviewed by Urdal, Ann .
  • Cell -surface cytokine receptors are further characterized by the presence of additional domains. These receptors are anchored in the cell membrane by a transmembrane domain characterized by a sequence of hydrophobic amino acid residues (typically about 21-25 residues) , which is commonly flanked by positively charged residues (Lys or Arg) . On the opposite end of the protein from the extracellular domain and separated from it by the transmembrane domain is an intracellular domain.
  • the novel receptor of the present invention was initially identified by the presence of the conserved WSXWS motif.
  • Analysis of a human cDNA clone encoding human Zcytor5 (SEQ ID NO:l) revealed an open reading frame encoding 422 amino acids (SEQ ID NO: 2) or an allelic variant reveals an open reading of 425 amino acid residues, SEQ ID NO: 3 and SEQ ID NO:4.
  • the isolated polynucleotides will hybridize to similar sized regions of SEQ ID NO:l, SEQ ID NO: 3, or SEQ ID NO : 5 , or a sequence complementary thereto, under stringent conditions.
  • stringent conditions are selected to be about 5°C lower than the thermal melting point (T m ) for the specific sequence at a defined ionic strength and pH.
  • T m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe.
  • Typical stringent conditions are those in which the salt concentration is at least about 0.02 M at pH 7 and the temperature is at least about 60°C.
  • the isolated polynucleotides of the present invention include DNA and RNA.
  • Methods for isolating DNA and RNA are well known in the art. It is generally preferred to isolate RNA from testis, including whole testis tissue extracts or testicular cells, such as Sertoli cells, Leydig cells, spermatogonia, or epididymis, although DNA can also be prepared using RNA from other tissues or isolated as genomic DNA.
  • Total RNA can be prepared using guanidine HCl extraction followed by isolation by centrifugation in a CsCl gradient [Chirgwin et al . , Biochemistry 18:52-94 (1979)] .
  • Poly (A) + RNA is prepared from total RNA using the method of Aviv and Leder, Proc . Natl . Acad. Sci . USA 65:1408-1412 (1972) .
  • Complementary DNA is prepared from poly (A) + RNA using known methods.
  • Polynucleotides encoding Zcytor5 polypeptides are then identified and isolated by, for example, hybridization or PCR.
  • sequences disclosed in SEQ ID NOS:l, 2, 3,4 represent single alleles of the human and SEQ ID NOs 5 and 6 of the rat Zcytor5 receptors. Allelic variants of these sequences can be cloned by probing cDNA or genomic libraries from different individuals according to standard procedures .
  • the present invention further provides counterpart receptors and polynucleotides from other species ("species orthologs").
  • Zcytor5 receptors from other mammalian species, including murine, porcine, ovine, bovine, canine, feline, equine, and other primate receptors.
  • Species orthologs of the human and macaque Zcytor5 receptors can be cloned using information and compositions provided by the present invention in combination with conventional cloning techniques.
  • a cDNA can be cloned using mRNA obtained from a tissue or cell type that expresses the receptor. Suitable sources of mRNA can be identified by probing Northern blots with probes designed from the sequences disclosed herein.
  • a library is then prepared from mRNA of a positive tissue or cell line.
  • a receptor- encoding cDNA can then be isolated by a variety of methods, such as by probing with a complete or partial human or macaque cDNA or with one or more sets of degenerate probes based on the disclosed sequences.
  • a cDNA can also be cloned using the polymerase chain reaction, or PCR (Mullis, U.S. Patent No. 4,683,202), using primers designed from the sequences disclosed herein.
  • the cDNA library can be used to transform or transfect host cells, and expression of the cDNA of interest can be detected with an antibody to the receptor. Similar techniques can also be applied to the isolation of genomic clones.
  • the polynucleotides of the present invention can be synthesized using DNA synthesizers.
  • the method of choice is the phosphoramidite method. If chemically synthesized double stranded DNA is required for an application such as the synthesis of a gene or a gene fragment, then each complementary strand is made separately.
  • the production of short genes 60 to 80 bp can be accomplished by synthesizing the complementary strands and then annealing them.
  • special strategies must be invoked, because the coupling efficiency of each cycle during chemical DNA synthesis is seldom 100%.
  • synthetic genes double-stranded are assembled in modular form from single-stranded fragments that are from 20 to 100 nucleotides in length.
  • One method for building a synthetic gene requires the initial production of a set of overlapping, complementary oligonucleotides, each of which is between 20 to 60 nucleotides long.
  • the sequences of the strands are planned so that, after annealing, the two end segments of the gene are aligned to give blunt or staggered ends.
  • Each internal section of the gene has complementary 3 ' and 5 ' terminal extensions that are designed to base pair precisely with an adjacent section.
  • synthetic genes can be designed with terminal sequences that facilitate insertion into a restriction endonuclease sites of a cloning vector and other sequences should also be added that contain signals for the proper initiation and termination of transcription and translation. See Glick, Bernard R. and Jack J. Pasternak, Molecular Biotechnology, Principles & Applications of Recombinant DNA, (ASM Press, Washington, D.C. 1994), Itakura, K. et al . Synthesis and use of synthetic oligonucleotides. Annu. Rev. Biochem . 53 : 323- 356 (1984), and Climie, S. et al . Chemical synthesis of the thymidylate synthase gene. Proc . Na tl . Acad. Sci . USA 81 :633-637 (1990) .
  • Another embodiment of the present invention provides for a peptide or polypeptide comprising an epitope-bearing portion of a polypeptide of the invention.
  • the epitope of the this polypeptide portion is an immunogenic or antigenic epitope of a polypeptide of the invention.
  • a region of a protein to which an antibody can bind is defined as an "antigenic epitope” . See for instance, Geysen, H.M. et al . , Proc . Na tl . Acad Sci . USA 81:3998-4002 (1984) .
  • Antigenic epitope-bearing peptides and polypeptides of the invention are therefore useful to raise antibodies, including monoclonal antibodies, that bind specifically to a polypeptide of the invention.
  • Antigenic epitope-bearing peptides and polypeptides of the present invention contain a sequence of at least nine, preferably between 15 to about 30 amino acids contained within the amino acid sequence of a polypeptide of the invention.
  • peptides or polypeptides comprising a larger portion of an amino acid sequence of the invention, containing from 30 to 50 amino acids, or any length up to and including the entire amino acid sequence of a polypeptide of the invention, also are useful for inducing antibodies that react with the protein.
  • the amino acid sequence of the epitope-bearing peptide is selected to provide substantial solubility in aqueous solvents (i.e., the sequence includes relatively hydrophilic residues and hydrophobic residues are preferably avoided) ; and sequences containing proline residues are particularly preferred.
  • All of the polypeptides shown in the sequence listing contain antigenic epitopes to be used according to the present invention, however, specifically designed antigenic epitopes include the peptides defined by SEQ ID NOs: 32-37.
  • the present invention also provides isolated receptor polypeptides that are substantially identical to the receptor polypeptides of SEQ ID NOs: 2, 4 and 6 and their species orthologs .
  • isolated is meant a protein or polypeptide that is found in a condition other than its native environment, such as apart from blood and animal tissue.
  • the isolated polypeptide is substantially free of other polypeptides, particularly other polypeptides of animal origin. It is preferred to provide the polypeptides in a highly purified form, i.e. greater than 95% pure, more preferably greater than 99% pure.
  • substantially homologous is used herein to denote polypeptides having 50%, preferably 60%, more preferably at least 80%, sequence identity to the sequences shown in SEQ ID NO: 2, 4, or 7 or their species orthologs. Such polypeptides will more preferably be at least 90% identical, and most preferably 95% or more identical to SEQ ID NO: 2, 4 or 6 or their species orthologs. Percent sequence identity is determined by conventional methods. See, for example, Al tschul et al . , Bull . Math . Bio . 48 : 603-616 (1986) and Henikoff and Henikoff, Proc. Natl . Acad. Sci . USA 85:10915-10919 (1992) .
  • Sequence identity of polynucleotide molecules is determined by similar methods using a ratio as disclosed above .
  • Polynucleotides generally a cDNA sequence, of the present invention encode the above-described polypeptides.
  • a cDNA sequence which encodes a polypeptide of the present invention is comprised of a series of codons, each amino acid residue of the polypeptide being encoded by a codon and each codon being comprised of three nucleotides. The amino acid residues are encoded by their respective codons as follows.
  • Alanine (Ala) is encoded by GCA, GCC, GCG or GCT;
  • Cysteine (Cys) is encoded by TGC or TGT;
  • Aspartic acid is encoded by GAC or GAT
  • Glutamic acid (Glu) is encoded by GAA or GAG
  • Phenylalanine is encoded by TTC or TTT Glycine (Gly) is encoded by GGA, GGC, GGG or
  • Histidine is encoded by CAC or CAT;
  • Isoleucine (lie) is encoded by ATA, ATC or ATT;
  • Lysine is encoded by AAA, or AAG; Leucine (Leu) is encoded by TTA, TTG, CTA, CTC,
  • Methionine (Met) is encoded by ATG;
  • Asparagine is encoded by AAC or AAT;
  • Proline is encoded by CCA, CCC, CCG or CCT ;
  • Glutamine (Gin) is encoded by CAA or CAG;
  • Arginine (Arg) is encoded by AGA, AGG, CGA, CGC, CGG or CGT;
  • Serine is encoded by AGC, AGT, TCA, TCC, TCG or TCT; Threonine (Thr) is encoded by ACA, ACC, ACG or
  • Valine (Val) is encoded by GTA, GTC, GTG or GTT; Tryptophan (Trp) is encoded by TGG; and Tyrosine (Tyr) is encoded by TAC or TAT.
  • mRNA messenger RNA
  • T thymine nucleotide
  • U uracil nucleotide
  • Substantially identical proteins and polypeptides are characterized as having one or more amino acid substitutions, deletions or additions. These changes are preferably of a minor nature, that is conservative amino acid substitutions (see Table 3) and other substitutions that do not significantly affect the folding or activity of the protein or polypeptide; small deletions, typically of one to about 30 amino acids; and small amino- or carboxyl-terminal extensions, such as an amino-terminal methionine residue, a small linker peptide of up to about 20-25 residues, or a small extension that facilitates purification (an affinity tag) , such as a poly-histidine tract, protein A, Nilsson et al . , EMBO J.
  • an affinity tag such as a poly-histidine tract, protein A, Nilsson et al . , EMBO J.
  • Essential amino acids in the receptor polypeptides of the present invention can be identified according to procedures known in the art, such as site- directed mutagenesis or alanine-scanning mutagenesis, Cunningham and Wells, Science 244 : 1081-1085 (1989); Bass et al . , Proc . Na tl . Acad . Sci . USA 88:4498-4502 (1991) .
  • site- directed mutagenesis or alanine-scanning mutagenesis Cunningham and Wells, Science 244 : 1081-1085 (1989); Bass et al . , Proc . Na tl . Acad . Sci . USA 88:4498-4502 (1991) .
  • single alanine mutations are introduced at every residue in the molecule, and the resultant mutant molecules are tested for biological activity (e.g., ligand binding and signal transduction) to identify amino acid residues that are critical to the activity of the molecule.
  • Sites of ligand-receptor interaction can also be determined by analysis of crystal structure as determined by such techniques as nuclear magnetic resonance, crystallography or photoaffinity labeling. See, for example, de Vos et al . , Science 255 : 306 - 312 (1992); Smith et al . , J. Mol . Biol . 224 : 899 - 904 (1992); Wlodaver et al . , FEBS Lett . 309 : 59 - 64 (1992). The identities of essential amino acids can also be inferred from analysis of homologies with related receptors .
  • Mutagenesis methods as disclosed above can be combined with high-throughput screening methods to detect activity of cloned, mutagenized receptors in host cells.
  • Preferred assays in this regard include cell proliferation assays and biosensor-based ligand-binding assays, which are described below.
  • Mutagenized DNA molecules that encode active receptors or portions thereof e.g., ligand-binding fragments
  • polypeptides that are substantially homologous to residues SEQ ID NOs:2, 4, 6, 17, 18, or 19 or allelic variants thereof and retain the ligand-binding properties of the wild-type receptor.
  • the receptor polypeptides of the present invention can be produced in genetically engineered host cells according to conventional techniques.
  • Suitable host cells are those cell types that can be transformed or transfected with exogenous DNA and grown in culture, and include bacteria, fungal cells, and cultured higher eukaryotic cells. Eukaryotic cells, particularly cultured cells of multicellular organisms, are preferred. Techniques for manipulating cloned DNA molecules and introducing exogenous DNA into a variety of host cells are disclosed by Sambrook et al . , Molecular Cloning: A Laboratory Manual , 2nd ed. , Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989, and Ausubel et al . , ibid.
  • a DNA sequence encoding a Zcytor5 receptor polypeptide is operably linked to other genetic elements required for its expression, generally including a transcription promoter and terminator, within an expression vector.
  • the vector will also commonly contain one or more selectable markers and one or more origins of replication, although those skilled in the art will recognize that within certain systems selectable markers may be provided on separate vectors, and replication of the exogenous DNA may be provided by integration into the host cell genome. Selection of promoters, terminators, selectable markers, vectors and other elements is a matter of routine design within the level of ordinary skill in the art . Many such elements are described in the literature and are available through commercial suppliers.
  • a secretory signal sequence also known as a leader sequence, prepro sequence or pre sequence
  • a secretory signal sequence also known as a leader sequence, prepro sequence or pre sequence
  • the secretory signal sequence may be that of the receptor, or may be derived from another secreted protein (e.g., t- PA) or synthesized de novo .
  • the secretory signal sequence is joined to the Zcytor5 DNA sequence in the correct reading frame.
  • Secretory signal sequences are commonly positioned 5 ' to the DNA sequence encoding the polypeptide of interest, although certain signal sequences may be positioned elsewhere in the DNA sequence of interest (see, e.g., Welch et al . , U.S. Patent No. 5,037,743; Holland et al., U.S. Patent No. 5,143,830).
  • Cultured mammalian cells are preferred hosts within the present invention.
  • Methods for introducing exogenous DNA into mammalian host cells include calcium phosphate-mediated transfection, Wigler et al . , Cell
  • Suitable cultured mammalian cells include the COS-1 (ATCC No. CRL 1650), COS-7 (ATCC No. CRL 1651), BHK (ATCC No. CRL 1632), BHK 570 (ATCC No. CRL 10314), 293 (ATCC No.
  • CRL 1573 Graham et al . , J. Gen . Virol . 36: 59- 12 , (1977) and Chinese hamster ovary (e.g. CHO-K1; ATCC No. CCL 61) cell lines. Additional suitable cell lines are known in the art and available from public depositories such as the American Type Culture Collection, Rockville, Maryland. In general, strong transcription promoters are preferred, such as promoters from SV-40 or cytomegalovirus. See, e . g. , U.S. Patent No. 4,956,288. Other suitable promoters include those from metallothionein genes (U.S. Patent Nos. 4,579,821 and 4,601,978,) and the adenovirus major late promoter.
  • Drug selection is generally used to select for cultured mammalian cells into which foreign DNA has been inserted. Such cells are commonly referred to as “transfectants”. Cells that have been cultured in the presence of the selective agent and are able to pass the gene of interest to their progeny are referred to as “stable transfectants.”
  • a preferred selectable marker is a gene encoding resistance to the antibiotic neomycin. Selection is carried out in the presence of a neomycin- type drug, such as G-418 or the like.
  • Selection systems may also be used to increase the expression level of the gene of interest, a process referred to as "amplification.” Amplification is carried out by culturing transfectants in the presence of a low level of the selective agent and then increasing the amount of selective agent to select for cells that produce high levels of the products of the introduced genes.
  • a preferred amplifiable selectable marker is dihydrofolate reductase, which confers resistance to methotrexate.
  • Other drug resistance genes e.g. hygromycin resistance, multi-drug resistance, puromycin acetyltransferase
  • hygromycin resistance multi-drug resistance
  • puromycin acetyltransferase can also be used.
  • eukaryotic cells can also be used as hosts, including insect cells, plant cells and avian cells. Transformation of insect cells and production of foreign polypeptides therein is disclosed by Guarino et al., U.S. Patent No. 5,162,222; Bang et al . , U.S. Patent No. 4,775,624; and WIPO publication WO 94/06463, which are incorporated herein by reference. The use of
  • Agrobacterium rhizogenes as a vector for expressing genes in plant cells has been reviewed by Sinkar et al . , J. Biosci . (Bangalore) 11:47-58 (1987).
  • Fungal cells including yeast cells, and particularly cells of the genus Saccharomyces , can also be used within the present invention, such as for producing receptor fragments or polypeptide fusions.
  • Methods for transforming yeast cells with exogenous DNA and producing recombinant polypeptides therefrom are disclosed by, for example, Kawasaki, U.S. Patent No. 4,599,311; Kawasaki et al . , U.S. Patent No. 4,931,373; Brake, U.S. Patent No. 4,870,008; Welch et al . , U.S. Patent No. 5,037,743; and Murray et al., U.S. Patent No. 4,845.
  • Transformed cells are selected by phenotype determined by the selectable marker, commonly drug resistance or the ability to grow in the absence of a particular nutrient (e.g., leucine).
  • a preferred vector system for use in yeast is the POT1 vector system disclosed by Kawasaki et al . (U.S. Patent No. 4,931,373), which allows transformed cells to be selected by growth in glucose-containing media.
  • Suitable promoters and terminators for use in yeast include those from glycolytic enzyme genes (see, e . g. , Kawasaki, U.S. Patent No. 4,599,311; Kingsman et al . , U.S. Patent No. 4,615,974; and Bitter, U.S. Patent No.
  • Transformed or transfected host cells are cultured according to conventional procedures in a culture medium containing nutrients and other components required for the growth of the chosen host cells.
  • suitable media including defined media and complex media, are known in the art and generally include a carbon source, a nitrogen source, essential amino acids, vitamins and minerals . Media may also contain such components as growth factors or serum, as required.
  • the growth medium will generally select for cells containing the exogenously added DNA by, for example, drug selection or deficiency in an essential nutrient which is complemented by the selectable marker carried on the expression vector or co- transfected into the host cell.
  • a novel receptor is produced by a cultured cell, and the cell is used to screen for ligands for the receptor, including the natural ligand, as well as agonists and antagonists of the natural ligand.
  • ligands for the receptor including the natural ligand, as well as agonists and antagonists of the natural ligand.
  • a cDNA or gene encoding the receptor is combined with other genetic elements required for its expression (e.g., a transcription promoter), and the resulting expression vector is inserted into a host cell.
  • Cells that express the DNA and produce functional receptor are selected and used within a variety of screening systems.
  • Mammalian cells suitable for use in expressing Zcytor5 receptors and transducing a receptor-mediated signal include cells that express a ⁇ -subunit, such as the human ⁇ c subunit.
  • a cell that is responsive to other cytokines that bind to receptors in the same subfamily, such as IL-3 or GM-CSF because such cells will contain the requisite signal transduction pathway (s) .
  • s signal transduction pathway
  • the cell is dependent upon an exogenously supplied hematopoietic growth factor for its proliferation.
  • Preferred cell lines of this type are the human TF-1 cell line (ATCC number CRL-2003) and the AML-193 cell line (ATCC number CRL- 9589) , which are GM-CSF-dependent human leukemic cell lines.
  • suitable host cells can be engineered to produce a ⁇ -subunit (e.g., b c ) or other cellular component needed for the desired cellular response.
  • a ⁇ -subunit e.g., b c
  • a baby hamster kidney (BHK) cell line can be transfected to express the human b c subunit (also known as KH97) as well as a Zcytor5 receptor.
  • the latter approach is advantageous because cell lines can be engineered to express receptor subunits from any species, thereby overcoming potential limitations arising from species specificity.
  • species orthologs of the human receptor cDNA can be cloned and used within cell lines from the same species, such as a mouse cDNA in the BaF3 cell line.
  • Cell lines that are dependent upon one hematopoietic growth factor, such as GM-CSF can thus be engineered to become dependent upon a Zcytor5 ligand.
  • Cells expressing functional receptor are used within screening assays.
  • a variety of suitable assays are known in the art. These assays are based on the detection of a biological response in a target cell.
  • One such assay is a cell proliferation assay. Cells are cultured in the presence or absence of a test compound, and cell proliferation is detected by, for example, measuring incorporation of tritiated thymidine or by colorimetric assay based on the metabolic breakdown of 3- (4,5- dimethylthiazol-2-yl) -2, 5-diphenyl tetrazolium bromide (MTT) (Mosman, J. Immunol . Meth . 65: 55-63 (1983).
  • An alternative assay format uses cells that are further engineered to express a reporter gene.
  • the reporter gene is linked to a promoter element that is responsive to the receptor-linked pathway, and the assay detects activation of transcription of the reporter gene.
  • a preferred promoter element in this regard is a serum response element, or SRE, e.g., Shaw et al . , Cell 56 : 563 -512 (1989) .
  • a preferred reporter gene is a luciferase gene, de Wet et al . , Mol . Cell . Biol . 7:725 (1987). Expression of the luciferase gene is detected by luminescence using methods known in the art (e.g., Baumgartner et al . , J. Biol . Chem.
  • Luciferase activity assay kits are commercially available from, for example, Promega Corp., Madison, WI .
  • Target cell lines of this type can be used to screen libraries of chemicals, cell-conditioned culture media, fungal broths, soil samples, water samples, and the like. For example, a bank of cell -conditioned media samples can be assayed on a target cell to identify cells that produce ligand. Positive cells are then used to produce a cDNA library in a mammalian expression vector, which is divided into pools, transfected into host cells, and expressed. Media samples from the transfected cells are then assayed, with subsequent division of pools, re-transfection, subculturing, and re-assay of positive cells to isolate a cloned cDNA encoding the ligand.
  • a natural ligand for the Zcytor5 receptor can also be identified by mutagenizing a cell line expressing the receptor and culturing it under conditions that select for autocrine growth. See WIPO publication WO 95/21930.
  • BaF3 cells expressing Zcytor5 and human b c are mutagenized, such as with 2- ethylmethanesulfonate (EMS) .
  • EMS 2- ethylmethanesulfonate
  • the cells are then allowed to recover in the presence of IL-3, then transferred to a culture medium lacking IL-3 and IL-4.
  • Surviving cells are screened for the production of a Zcytor5 ligand, such as by adding soluble receptor to the culture medium or by assaying conditioned media on wild-type BaF3 cells and BaF3 cells expressing the receptor.
  • hybrid receptor polypeptides include the use of hybrid receptor polypeptides. These hybrid polypeptides fall into two general classes. It is preferred that the second receptor be a hematopoietic cytokine receptor, such as mpl receptor (Souyri et al . , Cell 63 : 1137-1147 (1990).
  • the hybrid receptor will further comprise a transmembrane domain, which may be derived from either receptor.
  • a DNA construct encoding the hybrid receptor is then inserted into a host cell. Cells expressing the hybrid receptor are cultured in the presence of a ligand for the binding domain and assayed for a response.
  • This system provides a means for analyzing signal transduction mediated by Zcytor5 while using readily available ligands. This system can also be used to determine if particular cell lines are capable of responding to signals transduced by Zcytor5.
  • Cells found to express the ligand are then used to prepare a cDNA library from which the ligand-encoding cDNA can be isolated as disclosed above.
  • the present invention thus provides, in addition to novel receptor polypeptides, methods for cloning polypeptide ligands for the receptors .
  • agonist compounds are useful for stimulating proliferation and development of target cells in vi tro and in vivo .
  • agonist compounds are useful as components of defined cell culture media, and may be used alone or in combination with other cytokines and hormones to replace serum that is commonly used in cell culture.
  • Agonists are thus useful in specifically promoting the growth and/or development of testis-derived cells in culture.
  • Agonists and antagonists may also prove useful in the study of spermatogenesis and infertility.
  • Antagonists are useful as research reagents for characterizing sites of ligand-receptor interaction. In vivo, receptor agonists may find application in the treatment of male infertility. Antagonists of receptor function may be useful as male contraceptive agents.
  • the proposed cytokine binding domain of Zcytor5 appears to be closest to the Interleukin-6 ⁇ -chain or gpl30 (29% identity) .
  • the ligand for Zcytor5 is probably a member of the Interleukin-6 family of cytokines which at present includes: Interleukins-6 , -11, Leukemia Inhibitory Factor, Oncostatin M, Cardiotropin-1 and Ciliary Neurtrophic Factor.
  • Zcytor5 cDNAs isolated thus far do not encode a transmembrane domain nor any recognizable cytoplasmic signaling motifs characteristic of the Class I receptors. Structurally, Zcytor5 bears close similarity to ⁇ -subunit of the Ciliary Neutrophic Factor receptor (CNTF- R ⁇ ) . It is quite possible Zcytor5 does not have a transmembrane domain form and that the native molecule is phosphatidyl-inositol linked to the cell membrane in a manner similar to CNTF-R ⁇ .
  • CNTF- R ⁇ Ciliary Neutrophic Factor receptor
  • CT-1R Cardiotropin-1 receptor
  • LIV Receptor ⁇ LIV Receptor ⁇
  • CT-lR ⁇ uncharacterized 45kDa subunit that appears to be linked to the cell surface through a phosphatidyl-inositol linkage.
  • CT-lR ⁇ appears to be important for increased sensitivity and specificity of the receptor complex to Cardiotropin-1.
  • Zcytor5 is CT-lR ⁇ .
  • Cardiotropin-1 is a member of the Interleukin-6 family in which gpl30 and gpl90 are members of a tripartite complex is the Ciliary Neurotrophic Factor receptor.
  • CNTF-R ⁇ comprises the third receptor subunit and it mediates specificity and high affinity binding of the ligand complex.
  • CT-R ⁇ the proposed 45 kDa molecular mass of CT-R ⁇ agrees with that of Zcytor5 and the transcripts of CT-1 and Zcytor5 are found in similar tissues.
  • both transcripts are found in high levels in heart and in skeletal muscles, which is consistent with the observation that ligand and their receptor subunits are often co-expressed in the same tissue.
  • Cardiotropin-1 was originally cloned by function as a factor involved in cardiac hypertrophy, an adaptive response of heart muscle to an increased work load. Hypertrophy is characterized by reactivation of genes expressed during fetal heart development and by the accumulation of carsomeric proteins. If Zcytor5 proves to be the subunit that is important in the binding and specificity of Cardiotropin-1 to its receptor, Zcytor5 may prove to be a useful therapeutic antagonist to counteract the hypertrophic response to injury. Cardiotropin-1 has also been shown to promote survival of rat dopaminergic neurons in vi tro . An agonist-active soluble receptor may potentially be useful in the treatment of neuronal disorders such as Parkinson's disease.
  • Zcytor5 may also be used within diagnostic systems for the detection of circulating levels of ligand.
  • antibodies or other agents that specifically bind to Zcytor5 can be used to detect circulating receptor polypeptides. Elevated or depressed levels of ligand or receptor polypeptides may be indicative of pathological conditions, including cancer.
  • Zcytor5 receptor polypeptides can be prepared by expressing a DNA encoding a Zcytor5 polypeptide as described in SEQ ID NO:l, 3 and 5. To direct the export of the receptor domain from the host cell, the receptor DNA is linked to a second DNA segment encoding a secretory peptide. It is believed that amino acid 1-34 or in the alternative amino acid residues 1-30 are secretory peptides of SEQ ID NO : 2. For SEQ ID NO: 4, it is believed that residues 1-33 or in the alternative 1-29 are secretory peptides. For the rat sequence, it is believed that amino acid residues 1-40 define a secretory peptide.
  • peptides are generally cleaved after secretion by a mammalian cell.
  • other secretory peptides could be fused to the Zcytor ⁇ polypeptide, such as the t-PA secretory peptide.
  • a C-terminal extension such as a poly-histidine tag, substance P, FlagTM peptide (Hopp et al . , Biotechnology 6:1204-1210 (1988); available from Eastman Kodak Co., New Haven, CT) or another polypeptide or protein for which an antibody or other specific binding agent is available, can be fused to the receptor polypeptide.
  • a receptor extracellular domain can be expressed as a fusion with immunoglobulin heavy chain constant regions, typically an F c fragment, which contains two constant region domains and a hinge region but lacks the variable region.
  • immunoglobulin heavy chain constant regions typically an F c fragment
  • Such fusions are typically secreted as multimeric molecules wherein the Fc portions are disulfide bonded to each other and two receptor polypeptides are arrayed in closed proximity to each other. Fusions of this type can be used to affinity purify the cognate ligand from solution, as an in vi tro assay tool, to block signals in vi tro by specifically titrating out ligand, and as antagonists in vivo by administering them parenterally to bind circulating ligand and clear it from the circulation.
  • a Zcytor5-Ig chimera is added to a sample containing the ligand (e.g., cell-conditioned culture media or tissue extracts) under conditions that facilitate receptor-ligand binding (typically near-physiological temperature, pH, and ionic strength) .
  • the chimera-ligand complex is then separated by the mixture using protein A, which is immobilized on a solid support (e.g., insoluble resin beads) .
  • the ligand is then eluted using conventional chemical techniques, such as with a salt or pH gradient.
  • the chimera itself can be bound to a solid support, with binding and elution carried out as above.
  • the chimeras may be used in vivo to induce infertility.
  • Chimeras with high binding affinity are administered parenterally (e.g., by intramuscular, subcutaneous or intravenous injection) .
  • Circulating molecules bind ligand and are cleared from circulation by normal physiological processes.
  • the chimeras are bound to a support via the F c region and used in an ELISA format .
  • a preferred assay system employing a ligand- binding receptor fragment uses a commercially available biosensor instrument (BIAcoreTM, Pharmacia Biosensor, Piscataway, NJ) , wherein the receptor fragment is immobilized onto the surface of a receptor chip.
  • Biosensor instrument BIOSTM, Pharmacia Biosensor, Piscataway, NJ
  • a receptor fragment is covalently attached, using amine or sulfhydryl chemistry, to dextran fibers that are attached to gold film within the flow cell.
  • a test sample is passed through the cell.
  • ligand If ligand is present in the sample, it will bind to the immobilized receptor polypeptide, causing a change in the refractive index of the medium, which is detected as a change in surface plasmon resonance of the gold film.
  • This system allows the determination of on- and off-rates, from which binding affinity can be calculated, and assessment of stoichiometry of binding.
  • Ligand-binding receptor polypeptides can also be used within other assay systems known in the art . Such systems include Scatchard analysis for determination of binding affinity, Scatchard, Ann . NY Acad. Sci . 51 : 660- 672 (1949) and calorimetric assays, Cunningham et al . , Science 253:545-548 (1991); Cunningham et al . , Science 254 : 821 - 825 (1991) .
  • a receptor ligand-binding polypeptide can also be used for purification of ligand.
  • the receptor polypeptide is immobilized on a solid support, such as beads of agarose, cross-linked agarose, glass, cellulosic resins, silica-based resins, polystyrene, cross-linked polyacrylamide, or like materials that are stable under the conditions of use.
  • a solid support such as beads of agarose, cross-linked agarose, glass, cellulosic resins, silica-based resins, polystyrene, cross-linked polyacrylamide, or like materials that are stable under the conditions of use.
  • Methods for linking polypeptides to solid supports are known in the art, and include amine chemistry, cyanogen bromide activation, N- hydroxysuccinimide activation, epoxide activation, sulfhydryl activation, and hydrazide activation.
  • the resulting media will generally be configured in the form of a column, and fluids containing ligand are passed through the column one or more times to allow ligand to bind to the receptor polypeptide.
  • the ligand is then eluted using changes in salt concentration or pH to disrupt ligand-receptor binding.
  • Zcytor ⁇ polypeptides can also be used to prepare antibodies that specifically bind to Zcytor5 polypeptides.
  • the term "antibodies” includes polyclonal antibodies, monoclonal antibodies, antigen-binding fragments thereof such as F(ab')2 an -d Fab fragments, and the like, including genetically engineered antibodies. Antibodies are defined to be specifically binding if they bind to a Zcytor5 polypeptide with a K a of greater than or equal to 10 ⁇ /M. The affinity of a monoclonal antibody can be readily determined by one of ordinary skill in the art (see, for example, Scatchard, ibid . ) .
  • Zcytor5 polypeptides can also be used to prepare antibodies that specifically bind to Zcytor5 polypeptides. These antibodies can then be used to manufacture anti- idiotypic antibodies.
  • the term "antibodies” includes polyclonal antibodies, monoclonal antibodies, antigen-binding fragments thereof such as F(ab')2 and Fab fragments, and the like, including genetically engineered antibodies. Antibodies are defined to be specifically binding if they bind to a Zcytor5 polypeptide with a K a of greater than or equal to 10 7 /M. The affinity of a monoclonal antibody can be readily determined by one of ordinary skill in the art (see, for example, Scatchard, ibid. ) .
  • polyclonal and monoclonal antibodies are well known in the art (see for example, Sambrook et al . , Molecular Cloning: A Laboratory Manual , (Second Edition) (Cold Spring Harbor, NY, 1989) ; and Hurrell, J. G. R. , Ed., Monoclonal Hybridoma Antibodies : Techniques and Applications (CRC Press, Inc., Boca Raton, FL, 1982) .
  • polyclonal antibodies can be generated from a variety of warm-blooded animals such as horses, cows, goats, sheep, dogs, chickens, rabbits, mice, and rats.
  • the immunogenicity of a Zcytor5 polypeptide may be increased through the use of an adjuvant such as Freund's complete or incomplete adjuvant.
  • an adjuvant such as Freund's complete or incomplete adjuvant.
  • assays known to those skilled in the art can be utilized to detect antibodies which specifically bind to Zcytor5 polypeptides. Exemplary assays are described in detail in Antibodies : A Laboratory Manual , Harlow and Lane (Eds.), (Cold Spring Harbor Laboratory Press, 1988) .
  • assays include: concurrent immunoelectrophoresis, radio-immunoassays, radio- immunoprecipitations, enzyme-linked immunosorbent assays (ELISA), dot blot assays, inhibition or competition assays, and sandwich assays.
  • ELISA enzyme-linked immunosorbent assays
  • polyclonal antibodies can be generated by inoculating a variety of warm-blooded animals such as horses, cows, goats, sheep, dogs, chickens, rabbits, mice, hamsters, guinea pigs and rats with a ZcytorS polypeptide or a fragment thereof.
  • the immunogenicity of a Zcytor ⁇ polypeptide may be increased through the use of an adjuvant, such as alum (aluminum hydroxide) or Freund's complete or incomplete adjuvant.
  • an adjuvant such as alum (aluminum hydroxide) or Freund's complete or incomplete adjuvant.
  • Polypeptides useful for immunization also include fusion polypeptides, such as fusions of Zcytor ⁇ or a portion thereof with an immunoglobulin polypeptide or with maltose binding protein.
  • the polypeptide immunogen may be a full-length molecule or a portion thereof.
  • polypeptide portion is "hapten-like"
  • such portion may be advantageously joined or linked to a acromolecular carrier (such as keyhole limpet hemocyanin (KLH) , bovine serum albumin (BSA) or tetanus toxoid) for immunization.
  • a acromolecular carrier such as keyhole limpet hemocyanin (KLH) , bovine serum albumin (BSA) or tetanus toxoid
  • antibodies includes polyclonal antibodies, affinity-purified polyclonal antibodies, monoclonal antibodies, and antigen-binding fragments, such as F(ab'A and Fab proteolytic fragments. Genetically engineered intact antibodies or fragments, such as chimeric antibodies, Fv fragments, single chain antibodies and the like, as well as synthetic antigen- binding peptides and polypeptides, are also included.
  • Non-human antibodies may be humanized by grafting non- human CDRs onto human framework and constant regions, or by incorporating the entire non-human variable domains (optionally "cloaking" them with a human-like surface by replacement of exposed residues, wherein the result is a "veneered” antibody) . In some instances, humanized antibodies may retain non-human residues within the human variable region framework domains to enhance proper binding characteristics. Through humanizing antibodies, biological half-life may be increased, and the potential for adverse immune reactions upon administration to humans is reduced.
  • Alternative techniques for generating or selecting antibodies useful herein include in vi tro exposure of lymphocytes to Zcytor ⁇ protein or peptide, and selection of antibody display libraries in phage or similar vectors (for instance, through use of immobilized or labeled Zcytor ⁇ protein or peptide) .
  • Genes encoding polypeptides having potential Zcytor5 polypeptide binding domains can be obtained by screening random peptide libraries displayed on phage (phage display) or on bacteria, such as E. coli .
  • Nucleotide sequences encoding the polypeptides can be obtained in a number of ways, such as through random mutagenesis and random polynucleotide synthesis.
  • random peptide display libraries can be used to screen for peptides which interact with a known target which can be a protein or polypeptide, such as a ligand or receptor, a biological or synthetic macromolecule, or organic or inorganic substances.
  • a known target which can be a protein or polypeptide, such as a ligand or receptor, a biological or synthetic macromolecule, or organic or inorganic substances.
  • Techniques for creating and screening such random peptide display libraries are known in the art (Ladner et al . , US Patent NO. 5,223,409; Ladner et al . , US Patent NO.
  • Random peptide display libraries can be screened using the Zcytor5 sequences disclosed herein to identify proteins which bind to Zcytor5.
  • binding proteins which interact with Zcytor5 polypeptides can be used for tagging cells; for isolating homolog polypeptides by affinity purification; they can be directly or indirectly conjugated to drugs, toxins, radionuclides and the like. These binding proteins can also be used in analytical methods such as for screening expression libraries and neutralizing activity. The binding proteins can also be used for diagnostic assays for determining circulating levels of polypeptides; for detecting or quantitating soluble polypeptides as marker of underlying pathology or disease. These binding proteins can also act as Zcytor5 "antagonists" to block Zcytor5 binding and signal transduction in vi tro and in vivo .
  • Antibodies can also be generated gene therapy.
  • the animal is administered the DNA or RNA which encodes Zcytor ⁇ or an immunogenic fragment thereof so that cells of the animals are transfected with the nucleic acid and express the protein which in turn elicits an immunogenic response.
  • Antibodies which then are produced by the animal are isolated in the form of polyclonal or monoclonal antibodies .
  • Antibodies to Zcytor5 may be used for tagging cells that express the protein, for affinity purification, within diagnostic assays for determining circulating levels of soluble protein polypeptides, and as antagonists to block ligand binding and signal transduction in vi tro and in vivo .
  • polyclonal and monoclonal antibodies are well known in the art (see for example, Sambrook et al . , Molecular Cloning: A Laboratory Manual , Second Edi tion, Cold Spring Harbor, NY (1989) ; and Hurrell, J. G. R. , Ed., Monoclonal Hybridoma Antibodies : Techniques and Applications (CRC Press, Inc., Boca Raton, FL, 1982) .
  • polyclonal antibodies can be generated from a variety of warm-blooded animals such as horses, cows, goats, sheep, dogs, chickens, rabbits, mice, and rats.
  • antibodies against which bind to the claimed Zcytor5 polypeptides can be raised by immunization of animals with a Zcytor5 polypeptide or a fragment thereof.
  • the immunogenicity of a Zcytor5 polypeptide may be increased through the use of an adjuvant such as Freund's complete or incomplete adjuvant.
  • an adjuvant such as Freund's complete or incomplete adjuvant.
  • assays known to those skilled in the art can be utilized to detect antibodies which specifically bind to Zcytor5 polypeptides. Exemplary assays are described in detail in Antibodies : A Laboratory Manual , Harlow and Lane (Eds.) (Cold Spring Harbor Laboratory Press, 1988) .
  • assays include: concurrent immunoelectrophoresis, radio- immunoassays, radio- immunoprecipitations, enzyme- linked immunosorbent assays (ELISA), dot blot assays, inhibition or competition assays, and sandwich assays.
  • ELISA enzyme- linked immunosorbent assays
  • Antibodies to Zcytor5 are may be used for tagging cells that express the receptor, for affinity purification, within diagnostic assays for determining circulating levels of soluble receptor polypeptides, and as antagonists to block ligand binding and signal transduction in vi tro and in vivo . Uses
  • Zcytor5 may be a receptor for growth and/or maintenance factor in the thyroid heart and skeletal muscle.
  • ZcytorS could therefor be used to down regulate the effects of the factor by administering soluble Zcytor5 to the patient.
  • the soluble receptor could be used to lessen the effect of cardiotrophin-1 on cardiac pathologies.
  • Zcytor5 could also be used as a diagnostic to test for the presence of cardiotrophin-1 in the blood.
  • Zcytor5 can be used to discover other possible ligands which would bind to Zcytor ⁇ .
  • the present invention also provides reagents which will find use in diagnostic applications.
  • the Zcytor5 gene For example, the Zcytor5 gene.
  • a probe comprising the Zcytor5 DNA or RNA or a subsequence thereof can be used to determine if the Zcytor5 gene is present on chromosome 1 or if a mutation has occurred.
  • Antibodies to Zcytor5 could be used to purify Zcytor5 and as a therapeutic to modulate the effect of the Zcytor5 ligand.
  • the anti-idiotypic antibody to Zcytor5 could be used to purify the ligand of Zcytor5 and the administration of the anti-idiotypic antibody could be used to modulate the effect of the Zcytor5 ligand.
  • Example 1 The invention is further illustrated by the following non- limiting examples.
  • Example 1 The invention is further illustrated by the following non- limiting examples.
  • Human Zcytor5 was identified from expressed sequence tag (EST) 698365 (SEQ ID NO: 7) identified in an EST database.
  • the cDNA containing EST 698365 was obtained from Incyte Pharmaceuticals, Inc. as dried DNA. Upon reconstitution in water, the cDNA was transfected into E. coli strain DH10B. The plasmid was designated pSL8365. The EST in plasmid pSL8365 was sequenced, revealing an insert of 952 bp .
  • the GENE TRAPPER ® cDNA positive selection system (Life Technologies, Gaithersburg, MD) employing oligonucleotide ZC11,286 (SEQ ID NO: 8) was used to isolate the plasmid Hzcytor5-9 from a human lung cDNA library (obtained from Life Technologies Inc., Gaithersburg, MD) in accordance with the manufacturer's directions.
  • Hzcytor5-9 extended the sequence of pSL8365 by 459 bp.
  • the sequence present in Hzcytor5-9 allowed the isolation of an overlapping EST No. 485212 (SEQ ID NO: 9) , which extended the open reading frame of Hzcytor5-9 by a further 33 codons.
  • a cDNA encoding full-length Zcytor5 was isolated from a human testis cDNA library. (See Example 2 for the preparation of the human cDNA testis library.) The library was comprised of eighty pools of plasmid DNA, each pool comprised of 10,000 independent recombinants. The presence of Zcytor5 cDNA in each library pool was determined by PCR employing primers ZC11 . 663 (SEQ ID NO: 10) and ZC12,212 (SEQ ID NO: 11) . PCR was carried out using AMPLITAQ ® DNA polymerase (Perkin-Elmer) in buffer conditions recommended by the supplier.
  • AMPLITAQ ® DNA polymerase Perkin-Elmer
  • the amplification was carried out at 94° C for 1 minute followed by 30 cycles, each cycle consisting of 20 seconds at 94° C, 1 minute at 66° C and 7 minutes at 74° C.
  • Five cDNA pools were found to be positive for the 420 bp PCR product by agarose gel electrophoresis.
  • Plasmid DNA from one positive library pool was electrophoresed into DH10B cells and plated. Colony lifts were prepared using Hybond-N filters (Amersham; Arlington Heights, IL) according to the procedure provided by the manufacturer. Following denaturation and neutralization, DNA was cross-linked onto the filters with 1,200 ⁇ Joules of UV energy in a STRATALINKER ® (Stratagene Cloning
  • the PCR product probe was purified by agarose gel electrophoresis. 100 ng of the probe was labeled with P dCTP using the MULTI -PRIME ® DNA labeling system (Amersham) . Unincorporated label was removed with a NUCTRAP ® column (Stratagene) . Probe hybridization was carried out overnight at 65° C in EXPRESSHYB ® solution at a probe concentration of 1 xlO 6 cpm/ml . The filters were washed at 65° C in a wash buffer containing 0.25X SSC, 0.25 SDS and 1 mM EDTA.
  • SEQ ID NO: 3 Three positive signals were identified and were subjected to colony purification via a second round of filter hybridization. Sequence analysis of one positive clone, SEQ ID NO: 3 was found to be full length human Zcytor-5. Sequencing of a several overlapping clones revealed a second full-length sequence SEQ ID NO: 1 which is an allelic variant of SEQ ID NO : 3.
  • SEQ ID NO: 3 Three positive signals were identified and were subjected to colony purification via a second round of filter hybridization. Sequence analysis of one positive clone, SEQ ID NO: 3 was found to be full length human Zcytor-5. Sequencing of a several overlapping clones revealed a second full-length sequence SEQ ID NO: 1 which is an allelic variant of SEQ ID NO : 3.
  • SEQ ID NO: 3 Three positive signals were identified and were subjected to colony purification via a second round of filter hybridization. Sequence analysis of one positive clone, SEQ ID NO: 3 was found
  • First strand cDNA synthesis was initiated by the addition of 8 ⁇ l of 250 mM Tris-HCl, pH 8.3, 375 mM KCl, 15 mM MgCl 2 (5x SUPERSCRIPTTM buffer; GIBCO BRL) , 4 ⁇ l of 100 mM dithiothreitol (DTT) and 2 ⁇ l of a deoxynucleotide triphosphate solution containing 10 mM each of dATP, dGTP, dTTP and 5-methyl- dCTP (Pharmacia LKB Biotechnology Inc.) to the RNA-primer mixture.
  • DTT dithiothreitol
  • the reaction mixture was incubated at 45° C for 4 minutes followed by the addition of 10 ⁇ l of 200 U/ ⁇ l RNase H ⁇ reverse transcriptase (GIBCO BRL) .
  • the efficiency of the first strand synthesis was analyzed in a parallel reaction by the addition of 10 ⁇ Ci of 32 P- ⁇ dCTP to a 10 ⁇ l aliquot of the reaction mixture to label the reaction for analysis.
  • the reactions were incubated at 45° C for 1 hour followed by an incubation at 50° C for 15 minutes. Unincorporated P- ⁇ dCTP in the labeled reaction was removed by chromatography on a 400 pore size gel filtration column (CHROMA SPIN + TE-400TM; Clontech Laboratories Inc.).
  • Unincorporated nucleotides in the unlabeled first strand reaction were removed by twice precipitating the cDNA in the presence of 10 ⁇ g of glycogen carrier, 2.5 M ammonium acetate and 2.5 volume ethanol.
  • the unlabeled cDNA was resuspended in 50 ⁇ l water for use in second strand synthesis.
  • the length of the labeled first strand cDNA was determined by agarose gel electrophoresis. Second strand synthesis was performed on first strand cDNA under conditions that promoted first strand priming of second strand synthesis resulting in DNA hairpin formation.
  • the reaction mixture was assembled at room temperature and was comprised of 66 ⁇ l of the unlabeled first strand cDNA, 20 ⁇ l of 5X polymerase I buffer (100 mM Tris: HCl, pH 7.4, 500 mM KCl, 25 mM MgCl 2 , 50 mM (NH 4 ) 2 S0 4 ), 1 ⁇ l of 100 mM DTT, 1 ⁇ l of a solution containing 20 mM of each deoxynucleotide triphosphate, 3 ⁇ 1 of 5 mM ⁇ -NAD, l ⁇ l of 4 U/ ⁇ l of E.
  • 5X polymerase I buffer 100 mM Tris: HCl, pH 7.4, 500 mM KCl, 25 mM MgCl 2 , 50 mM (NH 4 ) 2 S0 4
  • 1 ⁇ l of 100 mM DTT 1 ⁇ l of a solution containing 20 mM of each deoxynucleotide triphosphat
  • Unincorporated P- ⁇ dCTP in the labeled reaction was removed by chromatography through a 400 pore size gel filtration column (Clontech Laboratories, Inc.) before analysis by agarose gel electrophoresis.
  • the unlabeled reaction was terminated by two extractions with phenol/chloroform and a chloroform extraction followed by ethanol precipitation in the presence of 2.5 M ammonium acetate.
  • the single-stranded DNA of the hairpin structure was cleaved using mung bean nuclease.
  • the reaction mixture contained 100 ⁇ l of second strand cDNA, 20 ⁇ l of lOx mung bean nuclease buffer (Stratagene Cloning Systems, La Jolla, CA) , 16 ⁇ l of 100 mM DTT, 51.5 ⁇ l of water and 12.5 ⁇ l of a 1:10 dilution of mung bean nuclease (Promega Corp.; final concentration 10.5 U/ ⁇ l) in mung bean nuclease dilution buffer.
  • the reaction was incubated at 37° C for 15 minutes.
  • the reaction was terminated by the addition of 20 ⁇ l of 1 M Tris: HCl, pH 8.0 followed by sequential phenol/chloroform and chloroform extractions as described above. Following the extractions, the DNA was precipitated in ethanol and resuspended in water.
  • the resuspended cDNA was blunt-ended with T4 DNA polymerase.
  • the cDNA which was resuspended in 138 ⁇ l of water, was mixed with 40 ⁇ l of 5X T4 DNA polymerase buffer (250 mM Tris: HCl, pH 8.0, 250 mM KCl, 25 mM MgCl 2 ) , 3 ⁇ l 0.1 M DTT, 5 ⁇ l of a solution containing 10 mM of each deoxynucleotide triphosphate and 4 ⁇ l of 1 U/ ⁇ l T4 DNA polymerase (Boehringer Mannheim Corp., Indianapolis, IN).
  • the reaction was terminated by the addition of 10 ⁇ l of 0.5 M EDTA followed by serial phenol/chloroform and chloroform extractions as described above.
  • the DNA was chromatographed through a 400 pore size gel filtration column (Clontech Laboratories Inc. Palo Alto, CA) to remove trace levels of protein and to remove short cDNAs less than about 400 bp in length.
  • the DNA was ethanol precipitated in the presence of 12 ⁇ g glycogen carrier and 2.5 M ammonium acetate and was resuspended in 10 ⁇ l of water. Based on the incorporation of P- ⁇ dCTP, the yield of cDNA was estimated to be about 2 ⁇ g from a starting template of 12.5 ⁇ g.
  • Eco RI adapters were ligated onto the 5 ' ends of the cDNA to enable cloning into a lambda phage vector.
  • a 10 ⁇ l aliquot of cDNA (containing about 2 ⁇ g of cDNA) and 11 ⁇ l of 65 pmole/ ⁇ l of Eco RI adapter (Pharmacia LKB Biotechnology Inc.) were mixed with 3 ⁇ l lOx ligase buffer (Promega Corp.), 3 ⁇ l 10 mM ATP and 3 ⁇ l of 15 U/ ⁇ l T4 DNA ligase (Promega Corp.). The reaction was incubated overnight (about 18 hours) at 12.5° C.
  • the reaction was terminated by the addition of 150 ⁇ l of water and 10 ⁇ l of 3 M Na acetate, followed by incubation at 65° C for 30 minutes. After incubation, the cDNA was extracted with phenol/chloroform and chloroform as described above and precipitated in the presence of 2.5 M ammonium acetate and 1.2 volume of isopropanol. Following centrifugation, the cDNA pellet was washed with 70% ethanol, air dried and resuspended in 89 ⁇ l water.
  • the cDNA was digested with Sst- I resulting in a cDNA having 5' Eco RI and 3' Sst- I cohesive ends.
  • the Sst- I restriction site at the 3' end of the cDNA had been previously introduced through primer ZC2938 (SEQ ID NO: 12) .
  • Restriction enzyme digestion was carried out in a reaction containing 89 ⁇ l of cDNA described above, 10 ⁇ l of 6 mM Tris: HCl, 6 mM MgCl 2 , 150 mM NaCl, 1 mM DTT (lOx D buffer; Promega Corp., Madison, WI) and 1 ⁇ l of 12 U/ ⁇ l Not I (Promega Corp.) . Digestion was carried out at 37° C for 1 hour. The reaction was terminated by serial phenol/chloroform and chloroform extractions.
  • the cD ⁇ A was ethanol precipitated, washed with 70% ethanol, air dried and resuspended in 20 ⁇ l of lx gel loading buffer (10 mM Tris: HCl, pH 8.0 , 1 mM EDTA, 5% glycerol and 0.125% bromphenol blue).
  • the resuspended cD ⁇ A was heated to 65° C for 5 minutes, cooled on ice and electrophoresed on a 0.8% low melt agarose gel (SEA PLAQUE GTGTM low melt agarose; FMC Corp.) . Unincorporated adapters and cD ⁇ A below 1.6 kb in length were excised from the gel . The electrodes were reversed, and the cD ⁇ A was electrophoresed until concentrated near the lane of origin. The area of the gel containing the concentrated cD ⁇ A was excised and placed in a microfuge tube, and the approximate volume of the gel slice was determined. A 300 ⁇ l aliquot of water, approximately three times the volume of the gel slice, was added to the tube.
  • SEA PLAQUE GTGTM low melt agarose FMC Corp.
  • the agarose was then melted by heating to 65° C for 15 minutes. Following equilibration of the sample to 42° C, 10 ⁇ l of 1 U/ ⁇ l ⁇ -agarose I ( New England Biolabs, Inc.) was added, and the mixture was incubated for 90 minutes to digest the agarose. After incubation, 40 ⁇ l of 3 M Na acetate was added to the sample, and the mixture was incubated on ice for 15 minutes. The sample was centrifuged at 14,000 x g for 15 minutes at room temperature to remove undigested agarose .
  • the cDNA in the supernatant was ethanol precipitated, washed in 70% ethanol, air-dried and resuspended in 37 ⁇ l of water for the kinase reaction to phosphorylate the ligated Eco RI adapters .
  • the phosphorylated cDNA was ethanol precipitated in the presence of 2.5 M ammonium acetate, washed with 70% ethanol, air dried and resuspended in 12.5 ⁇ l water.
  • the concentration of the phosphorylated cDNA was estimated to be about 40 fmole/ ⁇ l.
  • a 300bp double stranded DNA probe for Northern analysis was prepared from pSL1034 by PCR using oligonucleotide primers ZC 10,787 (SEQ ID NO: 13) and ZC 11,097 (SEQ ID NO:14).
  • the 300 bp PCR fragment was gel- purified using a QIAQUICK ® purification kit (Qiagen Inc., Chatsworth, CA) and random-primer labeled using a MULTIPRIME ® kit (Amersham Corp.). Labeled cDNA was purified from free counts using a Stratagene push column.
  • a single transcript of ⁇ 2.3 kb was detected after exposure to film.
  • the transcript was present in highest abundance in placenta, thyroid, heart and skeletal muscle with lower levels in prostate and trachea. Trace mRNA levels were found in kidney, pancreas, testis, small intestine, colon, lymph node, adrenal cortex and bone marrow.
  • Zcytor5 was mapped to chromosome 19 using the commercially available version of the "Stanford G3 Radiation Hybrid Mapping Panel” (Research Genetics, Inc., Huntsville, AL) .
  • the "Stanford G3 RH Panel” contains PCRable DNAs from each of 83 radiation hybrid clones of the whole human genome, plus two control DNAs (the RM donor and the A3 recipient) .
  • a publicly available WWW server http : //shgc- www.stanford.edu
  • Each of the 85 PCR reactions consisted of 2 ⁇ l 10X KlenTaq PCR reaction buffer (CLONTECH Laboratories, Inc., Palo Alto, CA) , 1.6 ⁇ l dNTPs mix (2.5 mM each, PERKIN-ELMER, Foster City, CA) , 1 ⁇ l sense primer, (SEQ ID NO: 13) 5' TAT GGC CAG GAC AAC ACA 3', 1 ⁇ l antisense primer, (SEQ ID NO: 14), 5' ATA GGG CGT AAA GAG AGC 3', 2 ⁇ l "RediLoad” (Research Genetics, Inc., Huntsville, AL) , 0.4 ⁇ l 50X Advantage KlenTaq Polymerase Mix (Clontech Laboratories, Inc.), 25 ng of DNA from an individual hybrid clone or control and x ⁇ l ddH20 for a total volume of 20 ⁇ l .
  • the reactions were overlaid with an equal amount of mineral oil and sealed.
  • the PCR cycler conditions were as follows: an initial 1 cycle 5 minute denaturation at 95°C, 35 cycles of a 1 minute denaturation at 95°C, 1 minute annealing at 66°C and 1.5 minute extension at 72°C, followed by a final 1 cycle extension of 7 minutes at 72°C.
  • the reactions were separated by electrophoresis on a 2% agarose gel (Life Technologies, Gaithersburg, MD) .
  • the results showed linkage of Zcytor5 to the framework marker WI-7289 with a LOD score of >10 and at a distance of 14.67cR_10000 from the marker.
  • Rat Zcytor ⁇ cDNA encoding Zcytor5 was isolated from an amplified Rat testis cDNA library with a probe that was generated by primers ZC12212 (SEQ ID NO: 11) and ZC10785 (SEQ ID NO: 15) and 10 ng of plasmid pSL85212 as a template obtained from cDNA containing EST 698365 as described in Example 1.
  • the probe was prepared by PCR by combining 1 ⁇ l containing 10 ng of pSL85212, 1 ⁇ l of ZC12212 having a concentration of 20 pmole/ ⁇ l, l ⁇ l of ZC10785 having a concentration of 20 pmole/ ⁇ l, 0.5 ⁇ l of dNTP having a concentration of 20 mM of dATP, dGTP, dCTP and dTTP, 5 ⁇ l of 10X Klentaq polymerase buffer (Clontech) 5 ⁇ l Klentaq DNA polymerase (Clontech) and 39.5 ⁇ l water.
  • the amplification was carried out at 94° C for 1 minute followed by 30 cycles, each cycle consisting of 15 seconds at 95° C, 20 seconds at 62° C and 1 minutes at 68° C.
  • the reaction had a final incubation at 68° C for 10 minutes.
  • the resulting PCR product was diluted 1:100 with water.
  • Four ⁇ l of the diluted PCR product was re-amplified using the above-described conditions and the resultant PCR product was further purified by electrophoresis on low- melt agarose gel .
  • the DNA probe was recovered from low- melt gel by digestion with ⁇ -Agarose I digestion.
  • the rat Zcytor5 gene was then cloned from a rat testis library which was constructed as described below in Example 6.
  • the library was first amplified by plating 3.10 plaque forming units (pfu) from the previously constructed primary library onto 98 150 mm NZY plates. Ten ml of serum medium was added to each plate and was incubated for several hours at room temperature. Following incubation, the phage lysates were collected and pooled to yield the amplified phage library.
  • Filter pre- hybridization was carried out in a hybridization solution containing 5X SSC, 5X Denhardt solution, 0.2% SDS, 1 mM EDTA and heat denatured sheared salmon-sperm D ⁇ A at a final concentration of 100 ⁇ g/ml for 72 hours at 60° C.
  • probe D ⁇ A 75 ng of probe D ⁇ A was labeled with 32 P-dCTP using a MEGAPRIME ® labeling kit (Amersham) and was purified with a ⁇ UCTRAP ® column (Stratagene) .
  • the labeled probe was heat-denatured and added to fresh hybridization solution at a concentration of 1.5 x 10 cpm/ml .
  • the filters containing the phage particles were also added. Hybridization of the probes to the phage- containing filters was completed overnight at 45° C. Following hybridization, the filters were washed in a solution containing 0.25X SSC, 0.25% SDS and 1 mM EDTA at 50° C.
  • the washed filters were autoradiographed for 72 hours at -70° C with intensifying screens. Examination of the autoradiographs revealed multiple regions that hybridized with the labeled probe. Agar plugs were picked from 56 regions for plaque purification. Of the positive signals, eleven produce positive phagemids following secondary and tertiary hybridization screens. The plasmids within the positive phagemids were recovered using the EXASSIT/SOLRTM system according to the manufacturer's specifications. A clone designated pSLRatR5-l was sequenced and found to encode full length Rat Zcytor5 (SEQ ID NO: 5)
  • the rat first strand cDNA reaction contained 10 ⁇ l of rat testis poly d (T) -selected poly (A) + mRNA
  • First strand cDNA synthesis was initiated by the addition of 8 ⁇ l of first strand buffer (5x SUPERSCRIPTTM buffer; Life Technologies, Gaithersburg, MD) , 4 ⁇ l of 100 mM dithiothreitol, and 2 ⁇ l of a deoxynucleotide triphosphate solution containing 10 mM each of dATP, dGTP and 5-methyl-dCTP (Pharmacia LKB Biotechnology,
  • RNA-primer mixture Piscataway, NJ
  • the reaction mixture was incubated at 45° C for 2 minutes, followed by the addition of 10 ⁇ l of 200 U/ ⁇ l RNase H- reverse transcriptase (SUPERSCRIPT II®'" Life Technologies) .
  • the efficiency of the first strand synthesis was analyzed in a parallel reaction by the addition of 10 ⁇ Ci of 32 P- ⁇ dCTP to 5 ⁇ l aliquot from one of the reaction mixtures to label the reaction for analysis.
  • the reactions were incubated at 45°C for 1 hour followed by an incubation at 50° C for 10 minutes.
  • Unincorporated 32p_ ⁇ c jc ⁇ p in the labeled reaction was removed by chromatography on a 400 pore size gel filtration column (Clontech) .
  • the unincorporated nucleotides and primers in the unlabeled first strand retains were removed by chromatography on 400 pore size gel filtration column (Clontech) .
  • the length of labeled first strand cDNA was determined by agarose gel electrophoresis .
  • the second strand reaction contained 102 ⁇ l of the unlabeled first strand cDNA, 30 ⁇ l of 5x polymerase I buffer (125 mM Tris: HCl, pH 7.5, 500 mM KCl, 25 mM
  • a 10 ⁇ l aliquot from one of the second strand synthesis reactions was labeled by the addition of 10 ⁇ Ci 32 P- ⁇ dCTP to monitor the efficiency of second strand synthesis .
  • the reactions were incubated at 16° C for two hours, followed by the addition of 10 ⁇ l T4 DNA polymerase (10 U/ ⁇ l, Boerhinger Mannheim) and incubated for an additional 5 minutes at 16°C. Unincorporated 32 P- ⁇ dCTP in the labeled reaction was removed by chromatography through a 400 pore size gel filtration column (Clontech) before analysis by agarose gel electrophoresis.
  • the unlabeled was terminated by the addition of 20 ⁇ l 0.5 EDTA and extraction with phenol/ chloroform and chloroform followed by ethanol precipitation in the presence of 2.5 M ammonium acetate.
  • the yield of cDNA was estimated to be approximately 2 ⁇ g from starting mRNA template of 10 ⁇ g.
  • Eco RI adapters were ligated onto the 5 ' ends of the cDNA described above to enable cloning into an expression vector.
  • the cDNA was digested with Xho I, resulting in a cDNA having a 5' Eco RI cohesive end and a 3' Xho I cohesive end.
  • the Xho I restriction site at the 3 ' end of the cDNA had been previously introduced using the ZC6091 primer (SEQ ID NO : 3) .
  • Restriction enzyme digestion was carried out in a reaction mixture containing 25 ⁇ l of cDNA described above, 15 ⁇ l of lOx H Buffer (Boehringer Mannheim), 109 ⁇ l H 2 0, and 1.0 ⁇ l of 40
  • the cDNA was ethanol precipitated, washed with 70% ethanol, air dried and resuspended in 20 ⁇ l of lx gel loading buffer (10 mM Tris:HCl, pH 8.0 , 1 mM EDTA, 5% glycerol and 0.125% bromphenol blue).
  • the resuspended cDNA was heated to 65° C for 5 minutes, cooled on ice and electrophoresed on a 0.8% low melt agarose gel.
  • the contaminating adapters and cDNA below 0.6 Kb in length were excised from the gel.
  • the electrodes were reversed, and the cDNA was electrophoresed until concentrated near the lane origin.
  • the area of the gel containing the concentrated cDNA was excised and placed in a microfuge tube, and the approximate volume of the gel slice was determined.
  • An aliquot of water approximately three times the volume of the gel slice (300 ⁇ l) and 35 ⁇ l lOx ⁇ - agarose I buffer (New England Biolabs) was added to the tube, and the agarose was melted by heating to 65°C for 15 minutes.
  • 3 ⁇ l of 1 U/ ⁇ l ⁇ -agarose I (New England Biolabs) was added, and the mixture was incubated for 60 minutes at 45°C to digest the agarose.
  • the resulting cDNA was cloned into the lambda phage vector ⁇ ZapII that was predigested with Eco RI and Xho I and dephosphorylated (Stratagene Cloning Systems, La Jolla, CA) .
  • Ligation of the cDNA to the ⁇ ZapII vector was carried out in a reaction mixture containing 1.0 ⁇ l of prepared vector, 1.0 ⁇ l of rat testis cDNA, 1.0 ⁇ l 10X Ligase Buffer (Promega), 1.0 ⁇ l of 10 mM ATP, 5 ⁇ l water, and 1.0 ⁇ l of T4 DNA Ligase at 15 units/ml (Promega) .
  • the ligation mixture was incubated at 5°C-15°C overnight in a temperature gradient. After incubation, the ligation mixture was packaged into phage using GIGPACK III GOLD packaging extract (Stratagene Cloning Systems) and the resulting library was titered according to the manufacturer's specifications. SEQUENCE LISTING
  • GCC CAA TCC GCG CGG CGG CCG CCG CCG TTG CTG CCC CTG CTG CTC 162 Ala Gin Ser Ala Arg Arg Pro Pro Pro Leu Leu Pro Leu Leu Leu Leu Leu 10 15 20 25
  • MOLECULE TYPE protein
  • FRAGMENT TYPE internal
  • MOLECULE TYPE protein
  • FRAGMENT TYPE internal
  • MOLECULE TYPE Other

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention porte sur de nouveaux polypeptides récepteurs, sur des polynucléotides codant pour lesdits polypeptides, et sur des compositions associées. Ces polypeptides peuvent servir à abaisser le niveau de leurs ligands naturels. Les polynucléotides et leurs sous-séquences peuvent servir de sondes de diagnostique permettant de constater les mutations du chromosome 19. Les anticorps se fixant aux polypeptides peuvent servir à purifier les récepteurs et à empêcher la fixation des ligands sur les récepteurs.
PCT/US1998/008865 1997-05-01 1998-05-01 Recepteurs de mammiferes analogues de la cytokine WO1998049307A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU72760/98A AU7276098A (en) 1997-05-01 1998-05-01 Mammalian cytokine-like receptor

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US4528797P 1997-05-01 1997-05-01
US85003097A 1997-05-01 1997-05-01
US60/045,287 1997-05-01
US08/850,030 1997-05-01
US2389098A 1998-02-13 1998-02-13
US7472198P 1998-02-13 1998-02-13
US09/023,890 1998-02-13
US60/074,721 1998-02-13

Publications (1)

Publication Number Publication Date
WO1998049307A1 true WO1998049307A1 (fr) 1998-11-05

Family

ID=27487250

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/008865 WO1998049307A1 (fr) 1997-05-01 1998-05-01 Recepteurs de mammiferes analogues de la cytokine

Country Status (2)

Country Link
AU (1) AU7276098A (fr)
WO (1) WO1998049307A1 (fr)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999035264A1 (fr) * 1998-01-09 1999-07-15 Immunex Corporation Adn codant h14, et polypeptides h14
WO1999020755A3 (fr) * 1997-10-16 1999-07-29 Glaxo Group Ltd Nouveaux recepteurs de cytokine
WO1999037769A1 (fr) * 1998-01-22 1999-07-29 Regeneron Pharmaceuticals, Inc. Recepteurs orphelins
WO1999040195A1 (fr) * 1998-02-06 1999-08-12 Schering Corporation Proteines de recepteurs de mammiferes; reactifs et procedes apparentes
WO1999053066A1 (fr) * 1998-04-10 1999-10-21 Genetics Institute, Inc. U4, un membre de la superfamille des recepteurs de l'hematopoietine
WO2000053631A1 (fr) * 1999-03-11 2000-09-14 Schering Corporation Cytokines de mammifere : reactifs et procedes associes
WO2001004304A1 (fr) * 1999-07-07 2001-01-18 Zymogenetics, Inc. Recepteur de cytokine humaine
US6800460B1 (en) 1999-03-11 2004-10-05 Schering Corporation Mammalian cytokine complexes
US7517958B2 (en) 1999-07-07 2009-04-14 Zymogenetics, Inc. Interleukin-17 receptor homologue
US7622116B2 (en) 2006-02-10 2009-11-24 Zymogenetics, Inc. Method of treating inflammation using soluble IL-17RCX4
US7790676B2 (en) 2007-03-28 2010-09-07 Zymogenetics, Inc. Soluble IL-17RA/RC fusion proteins
US7842665B2 (en) 2005-09-28 2010-11-30 Zymogenetics, Inc. IL-17A and IL-17F antagonists
US7910540B2 (en) 2004-06-10 2011-03-22 Zymogenetics, Inc. Soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners and methods of using in inflammation
AU2018214147B2 (en) * 2009-01-12 2020-06-04 Cytomx Therapeutics, Inc Modified Antibody Compositions, Methods of Making and Using Thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011225A2 (fr) * 1996-09-11 1998-03-19 Amrad Operations Pty. Ltd. Nouveau recepteur d'hematopoietine et sequences genetiques codant ce dernier
WO1998031811A1 (fr) * 1997-01-16 1998-07-23 Genetics Institute, Inc. Membre de la superfamille des recepteurs d'hematopoietine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011225A2 (fr) * 1996-09-11 1998-03-19 Amrad Operations Pty. Ltd. Nouveau recepteur d'hematopoietine et sequences genetiques codant ce dernier
WO1998031811A1 (fr) * 1997-01-16 1998-07-23 Genetics Institute, Inc. Membre de la superfamille des recepteurs d'hematopoietine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL 15 June 1996 (1996-06-15), MARRA M ET AL: "me17b11.r1 Soares mouse embryo NbME13.5 14.5 Mus musculus cDNA clone 387741 5' similar to PIR:B38252 B38252 granulocyte colony-stimulating factor receptor precursor ;.", XP002075171 *
DATABASE EMBL 29 November 1996 (1996-11-29), MARRA M ET AL: "mj45d02.r1 Soares mouse embryo NbME13.5 14.5 Mus musculus cDNA clone 479043 5' similar to SW:IL6B_MOUSE Q00560 INTERLEUKIN-6 RECEPTOR BETA CHAIN PRECURSOR ;.", XP002075172 *
ELSON G C ET AL: "Cytokine-like factor-1, a novel soluble protein, shares homology with members of the cytokine type I receptor family.", JOURNAL OF IMMUNOLOGY, vol. 161, no. 3, 1 August 1998 (1998-08-01), pages 1371 - 1379, XP002075165 *

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999020755A3 (fr) * 1997-10-16 1999-07-29 Glaxo Group Ltd Nouveaux recepteurs de cytokine
WO1999035264A1 (fr) * 1998-01-09 1999-07-15 Immunex Corporation Adn codant h14, et polypeptides h14
WO1999037769A1 (fr) * 1998-01-22 1999-07-29 Regeneron Pharmaceuticals, Inc. Recepteurs orphelins
WO1999040195A1 (fr) * 1998-02-06 1999-08-12 Schering Corporation Proteines de recepteurs de mammiferes; reactifs et procedes apparentes
WO1999053066A1 (fr) * 1998-04-10 1999-10-21 Genetics Institute, Inc. U4, un membre de la superfamille des recepteurs de l'hematopoietine
US6800460B1 (en) 1999-03-11 2004-10-05 Schering Corporation Mammalian cytokine complexes
WO2000053631A1 (fr) * 1999-03-11 2000-09-14 Schering Corporation Cytokines de mammifere : reactifs et procedes associes
US7390481B2 (en) 1999-03-11 2008-06-24 Schering Corporation Mammalian cytokine complexes
US7612191B2 (en) 1999-07-07 2009-11-03 Zymogenetics, Inc. Polynucleotides encoding interleukin-17 receptor homologue
EP2241623A3 (fr) * 1999-07-07 2010-12-01 ZymoGenetics, Inc. Anti-corps monoclonal contre un récepteur de cytokine humain
JP2003504058A (ja) * 1999-07-07 2003-02-04 ザイモジェネティクス，インコーポレイティド ヒトサイトカイン受容体
EP1860188A3 (fr) * 1999-07-07 2008-08-27 ZymoGenetics, Inc. Récepteur de cytokine humain
US7517958B2 (en) 1999-07-07 2009-04-14 Zymogenetics, Inc. Interleukin-17 receptor homologue
US7521208B2 (en) 1999-07-07 2009-04-21 Zymogenetics, Inc. Vectors encoding interleukin-17 receptor homologue
WO2001004304A1 (fr) * 1999-07-07 2001-01-18 Zymogenetics, Inc. Recepteur de cytokine humaine
US7619071B2 (en) 1999-07-07 2009-11-17 Zymogenetics, Inc. Antibodies that bind interleukin-17 receptor homologue
JP4737903B2 (ja) * 1999-07-07 2011-08-03 ザイモジェネティクス， インコーポレイテッド ヒトサイトカイン受容体
EP1860188A2 (fr) 1999-07-07 2007-11-28 ZymoGenetics, Inc. Récepteur de cytokine humain
US7910701B2 (en) 1999-07-07 2011-03-22 Zymogenetics, Inc. Interleukin-17 receptor homologue
US7910540B2 (en) 2004-06-10 2011-03-22 Zymogenetics, Inc. Soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners and methods of using in inflammation
US8268773B2 (en) 2004-06-10 2012-09-18 Zymogenetics, Inc. Methods of treating multiple sclerosis (MS) using an IL-17A and IL-17F antagonist
US7842665B2 (en) 2005-09-28 2010-11-30 Zymogenetics, Inc. IL-17A and IL-17F antagonists
US7622116B2 (en) 2006-02-10 2009-11-24 Zymogenetics, Inc. Method of treating inflammation using soluble IL-17RCX4
US8093355B2 (en) 2006-02-10 2012-01-10 Zymogenetics, Inc. Soluble IL-17RCx4 and fusion proteins thereof
US7790676B2 (en) 2007-03-28 2010-09-07 Zymogenetics, Inc. Soluble IL-17RA/RC fusion proteins
US8084231B2 (en) 2007-03-28 2011-12-27 Zymogenetics, Inc. Soluble IL-17RA/RC fusion proteins and related methods
AU2018214147B2 (en) * 2009-01-12 2020-06-04 Cytomx Therapeutics, Inc Modified Antibody Compositions, Methods of Making and Using Thereof
US10875913B2 (en) 2009-01-12 2020-12-29 Cytomx Therapeutics, Inc. Methods of treatment using activatable anti-EGFR antibodies

Also Published As

Publication number Publication date
AU7276098A (en) 1998-11-24

Similar Documents

Publication Publication Date Title
CA2281491C (fr) Recepteur "zcytor7" de cytokine
EP0910635B1 (fr) Recepteur de cytokines hematopoietiques
EP1003863B1 (fr) Recepteur 11 de cytokines de mammiferes
EP0615451B1 (fr) Nouvelle cytokine de fixation sur cd30
CA2188279C (fr) Recepteurs de l'interleukine-15
WO1998049307A1 (fr) Recepteurs de mammiferes analogues de la cytokine
CA2418950A1 (fr) Recepteurs de cytokines zcytor 11 solubles
WO1997033913A1 (fr) Recepteur de cytokine exprime dans les cellules du testicule
US6271343B1 (en) Mammalian cytokine-like receptor 5
US20060110800A1 (en) Testis-specific receptor
JP2001525195A (ja) 哺乳類アルファ螺旋蛋白質−１
US20020058801A1 (en) Mammalian alpha helical protein-1

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998547437

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载